The Influence of Doctor-patient Communication on Patients' Willingness to Take Medication

NCT ID: NCT03046940

Last Updated: 2017-06-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-15

Study Completion Date

2017-06-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The experiment aims at investigating whether the doctor-patient communication has an influence on patients' willingness to take medication. Patients' attitude towards the medication is manipulated via a critical film sequence. Afterwards patients of the two experimental groups have a communication with one of the investigators of the study. Patients are told that the investigator is a medical doctor. The "doctors" either communicate in a patient-centered or doctor-centered style with the patient. Patients in the control group do not have the possibility to talk to a "medical doctor". Afterwards patients are offered the aforementioned pill that is supposed to be a cognitive enhancer (actually placebo pill). Pill intake is voluntary. The investigators hypothesize that patients in the experimental group with the patient-centered style of communication are more likely to take the pill than patients in the experimental group with the doctor-centered style of communication or patients in the control group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

No communication with a doctor

Group Type NO_INTERVENTION

No interventions assigned to this group

Patient-centered

Participants communicate with a doctor that uses a patient-centered style of communication

Group Type EXPERIMENTAL

Patient-centered style of communication

Intervention Type OTHER

Different doctor-patient communication

Doctor-centered

Participants communicate with a doctor that uses a doctor-centered style of communication

Group Type EXPERIMENTAL

Doctor-centered style of communication

Intervention Type OTHER

Different doctor-patient communication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient-centered style of communication

Different doctor-patient communication

Intervention Type OTHER

Doctor-centered style of communication

Different doctor-patient communication

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female
* between 18 and 35 years
* healthy
* adequate ability to see
* fluent in German (reading and writing)

Exclusion Criteria

* regular intake of cognitive enhancers/medication that enhances concentration
* intake of psychotropic drugs
* medical or pharmacy students, advanced psychology students
* participants who know the investigators
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philipps University Marburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Winfried Rief

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Winfried Rief, PhD, Prof

Role: PRINCIPAL_INVESTIGATOR

Philipps University Marburg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Psychology and Psychotherapy, Philipps-University Marburg

Marburg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-37v-r

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.